Ibex Medical Analytics Overview
Ibex Medical Analytics uses artificial intelligence technology to develop clinical-grade solutions designed to detect cancer as accurately as a human pathologist. The companys Galen platform uses algorithms to analyze images, detect and grade cancer in biopsies, and point to other findings with high clinical importance, helping pathologists to reduce diagnostic error rates and enable a more efficient workflow. Deployed worldwide, Ibexs Galen Prostate and Galen Breast are AI-based cancer detection solutions used in routine clinical practice in pathology labs, with demonstrated success in detecting missed cancer cases. In addition, the company is developing computational prognostic and predictive tests that will enable enhanced patient population stratification and quicker personalized treatment selection.
Cumulative Funding Raised Over Time ($)
$2.6MFeb 2018
$13.6MMar 2019
$51.6MMar 2021
$61.6MNov 2022
$116.6MSep 2023
Latest News
The former Battery Ventures and Goldman Sachs executive steps in after Ibex raised a fresh $106M early-stage fund and $40M secondary fund.
Growth-Positive
Ibex Medical raises $55 million Series C for AI-powered cancer diagnostics | CTech
Ibex Medical Analytics, an Israeli startup that develops AI-powered cancer diagnostics, has raised $55 million in a Series C financing round. The round was led by 83North, with participation from Sienna Venture Capital and existing investors Octopus Ventures, aMoon, Planven Entrepreneur Ventures, and Dell Technologies Capital. This brings the total funding to over $100 million since the companys inception in 2016. Ibex plans to use the funds to expand its footprint in the United States and accelerate the growth of its product portfolio.
InvestmentExpand
growth-positive
Ibex Medical Analytics Secures $10M Funding from Kreos Capital
Ibex Medical Analytics has secured $10 million in funding from Kreos Capital to accelerate its AI deployments and support new customer deployments. The funding will also be used to strengthen and expand Ibexs US team and fuel further business growth. Ibex plans to focus on adding new applications to its Galen platform and enhancing collaboration with leading digital pathology providers. The company has recently signed major contracts and gained new customers across multiple geographies. The funding from Kreos Capital adds to Ibexs previous funding of $52 million. Ibex is a leader in AI-powered cancer diagnostics and its Galen technology is widely used in pathology for cancer diagnosis.
InvestmentExpand
growth-positive
Ibex Announces Galen™ 3.0 Cancer Diagnostics Platform
Ibex Medical Analytics has launched Galen 3.0, an AI-powered solution for cancer diagnosis. Galen 3.0 offers new detection capabilities and features to support pathologists in diagnosing multiple tissue types. It is the first and most widely deployed AI technology in pathology and is used in routine clinical practice worldwide. The solution improves the quality of cancer diagnosis, reduces turnaround time, boosts productivity, and enhances user experience for pathologists. Galen 3.0 incorporates the latest AI algorithms for detecting cancer and other clinically relevant features. It also includes an open API for seamless integration with image management solutions and digital pathology workflow solutions. Ibex Medical Analytics presented Galen 3.0 at the European Congress of Pathology in September 2022.
CustomersPartners
growth-positive
Ibex wins CE mark for AI-powered gastric cancer detection tech
Ibex Medical Analytics has received CE mark approval for its Galen gastric cancer detection solution. The AI-powered solution uses machine learning technology to analyze biopsy slides and detect gastric cancer, H. pylori, and other clinical findings. The approval follows a successful clinical study that demonstrated high accuracy in detecting various types of gastric cancer. Ibexs CEO will relocate to the U.S. to lead the companys North American expansion efforts. The approval will enable Ibex to expand the usage of AI technology and provide pathologists with new insights, improving the quality of cancer diagnosis and care.
CustomersManagement Changes
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $116.6M |
| Last funding | $55M |
| Stage | C |
| Rounds | 5 |
| Investors | 10 |
Team Members
5
Employees: 51-200
Web & Social Links
| Website | ibex-ai.com/ |
| Careers | Careers page |
Locations
Rokach Boulevard 97, Tel Aviv-Yafo, Israel
Photos & Videos
3 item(s)
Ibex Medical Analytics Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsMedical Decision SupportTarget Customer
Healthcare & Life SciencesHealthcareProvidersLaboratoriesConsumersDemographics & FamilyWomenCore Technology
Artificial IntelligenceMachine LearningComputer VisionTags (19)
artificial-intelligencedoctorsdigital-healthcarediagnosticsmachine-learningmedical-image-analysisoncologylaboratoriesprecision-medicinebiopsycomputer-visiondecision-supporthospitalsbig-dataclinicsemrwomen-healthwomenpersonalizationGeographic Markets
IsraelUnited KingdomAmericasGermanyFranceIbex Medical Analytics Financials
$116.6M
Total funding
Undisclosed
Capital raised
$55M
Last funding
C
Funding stage
5
Total rounds
10
Investors
Cumulative Funding Raised Over Time ($)
$2.6MFeb 2018
$13.6MMar 2019
$51.6MMar 2021
$61.6MNov 2022
$116.6MSep 2023
Private Equity Funding
C Round
Sep 2023
$55M
83North (Lead)
,
Sienna Venture Capital, aMoon Fund, Planven Entrepreneur Ventures, Dell Technologies Capital, Octopus Ventures, LIP Ventures
Undisclosed Round
Nov 2022
$10M
Kreos Capital (Lead)
B Round
Mar 2021
$38M
Octopus Ventures (Lead)
,
aMoon Fund, Dell Technologies Capital, 83North, Planven Entrepreneur Ventures
A Round
Mar 2019
$11M
aMoon Fund (Lead)
,
Kamet Ventures, AXA Insurance , Dell Technologies Capital, 83North
Seed
Feb 2018
$2.6M
Kamet Ventures
Ibex Medical Analytics Lifecycle
Cumulative Funding Raised Over Time
$2.6MFeb 2018
$13.6MMar 2019
$51.6MMar 2021
$61.6MNov 2022
$116.6MSep 2023
All Events
C Round
Sep 2023
$55M
83North (Lead)
,
Sienna Venture Capital, aMoon Fund, Planven Entrepreneur Ventures, Dell Technologies Capital, Octopus Ventures, LIP Ventures
Undisclosed Round
Nov 2022
$10M
Kreos Capital (Lead)
B Round
Mar 2021
$38M
Octopus Ventures (Lead)
,
aMoon Fund, Dell Technologies Capital, 83North, Planven Entrepreneur Ventures
A Round
Mar 2019
$11M
aMoon Fund (Lead)
,
Kamet Ventures, AXA Insurance , Dell Technologies Capital, 83North
Seed
Feb 2018
$2.6M
Kamet Ventures
Ibex Medical Analytics News
36 articlesThe former Battery Ventures and Goldman Sachs executive steps in after Ibex raised a fresh $106M early-stage fund and $40M secondary fund.
Growth-Positive
Ibex Medical raises $55 million Series C for AI-powered cancer diagnostics | CTech
Ibex Medical Analytics, an Israeli startup that develops AI-powered cancer diagnostics, has raised $55 million in a Series C financing round. The round was led by 83North, with participation from Sienna Venture Capital and existing investors Octopus Ventures, aMoon, Planven Entrepreneur Ventures, and Dell Technologies Capital. This brings the total funding to over $100 million since the companys inception in 2016. Ibex plans to use the funds to expand its footprint in the United States and accelerate the growth of its product portfolio.
InvestmentExpand
growth-positive
Ibex Medical Analytics Secures $10M Funding from Kreos Capital
Ibex Medical Analytics has secured $10 million in funding from Kreos Capital to accelerate its AI deployments and support new customer deployments. The funding will also be used to strengthen and expand Ibexs US team and fuel further business growth. Ibex plans to focus on adding new applications to its Galen platform and enhancing collaboration with leading digital pathology providers. The company has recently signed major contracts and gained new customers across multiple geographies. The funding from Kreos Capital adds to Ibexs previous funding of $52 million. Ibex is a leader in AI-powered cancer diagnostics and its Galen technology is widely used in pathology for cancer diagnosis.
InvestmentExpand
growth-positive
Ibex Announces Galen™ 3.0 Cancer Diagnostics Platform
Ibex Medical Analytics has launched Galen 3.0, an AI-powered solution for cancer diagnosis. Galen 3.0 offers new detection capabilities and features to support pathologists in diagnosing multiple tissue types. It is the first and most widely deployed AI technology in pathology and is used in routine clinical practice worldwide. The solution improves the quality of cancer diagnosis, reduces turnaround time, boosts productivity, and enhances user experience for pathologists. Galen 3.0 incorporates the latest AI algorithms for detecting cancer and other clinically relevant features. It also includes an open API for seamless integration with image management solutions and digital pathology workflow solutions. Ibex Medical Analytics presented Galen 3.0 at the European Congress of Pathology in September 2022.
CustomersPartners
growth-positive
Ibex wins CE mark for AI-powered gastric cancer detection tech
Ibex Medical Analytics has received CE mark approval for its Galen gastric cancer detection solution. The AI-powered solution uses machine learning technology to analyze biopsy slides and detect gastric cancer, H. pylori, and other clinical findings. The approval follows a successful clinical study that demonstrated high accuracy in detecting various types of gastric cancer. Ibexs CEO will relocate to the U.S. to lead the companys North American expansion efforts. The approval will enable Ibex to expand the usage of AI technology and provide pathologists with new insights, improving the quality of cancer diagnosis and care.
CustomersManagement Changes
growth-positive
Dedalus and Ibex announce a strategic partnership to bring the power of artificial intelligence to digital pathology
Dedalus Group and Ibex Medical Analytics have announced a strategic partnership to bring the power of artificial intelligence to digital pathology. The partnership will integrate Ibexs clinical-grade AI algorithms into Dedalus end-to-end digital pathology solution, benefiting pathologists and patients through enhanced quality of diagnosis. Dedalus is a leading healthcare and diagnostic software provider in Europe, while Ibex is the market leader in AI-powered cancer diagnostics. The partnership aims to address the increasing demand for pathology services and the global shortage of trained pathologists. Dedalus has deployments in over 5700 laboratories globally, while Ibexs Galen platform is deployed in labs worldwide as part of everyday clinical practice.
Partners
growth-positive
Ibex מגייסת עובדי היי-טק לסיוע בגילוי ממוחשב של סרטן - וואלה! כסף
Ibex Medical Analytics, a global leader in AI-based cancer detection and machine learning, is expanding into new markets and recruiting employees in Israel and worldwide. The companys technology allows for the interpretation of biopsy samples and assists pathologists in diagnosing cancer quickly, efficiently, and with a high level of accuracy. Ibexs products are embedded in hospitals and laboratories around the world. The company is currently recruiting for a variety of roles in its Tel Aviv development center.
Expand
growth-positive
Ibex and Sana Kliniken Berlin-Brandenburg Partner to Bring AI-powered Cancer Diagnostics to Germany
Ibex Medical Analytics and Sana Kliniken Berlin-Brandenburg have announced the first deployment and clinical evaluation in Germany of an AI platform that supports pathologists during routine cancer diagnosis. The partnership aims to improve the quality and efficiency of cancer diagnosis using AI technology. Sana Kliniken Berlin-Brandenburg is digitizing its pathology labs and will use Ibexs Galen platform in routine practice to evaluate the clinical impact of using AI in diagnosing multiple tissue types. The partnership demonstrates Sanas commitment to improving patient care and adopting AI and digital pathology technologies in cancer care.
PartnersCustomers
growth-positive
Ibex Granted FDA Breakthrough Device Designation
Ibex Medical Analytics has been granted Breakthrough Device Designation by the FDA for its AI-powered cancer diagnostics platform. The designation will help expedite the clinical review and regulatory approval process. Ibexs Galen platform uses AI algorithms to assist pathologists in improving the quality of cancer diagnosis, reducing diagnosis time, and increasing productivity. The platform has already shown positive outcomes in clinical studies and is used globally in everyday clinical practice. The FDA designation is seen as a significant step in making this technology widely available in the United States. Ibex is committed to providing tools for pathologists to ensure accurate and timely diagnoses, while also increasing efficiency and accuracy in pathology labs and health systems.
PartnersCustomers
growth-positive
Ibex obtains CE Mark for AI-powered breast cancer detection
Ibex Medical Analytics has received a CE Mark for its Galen Breast solution, an AI-powered diagnostic tool for pathologists to detect various types of breast cancer. The solution has been ordered by multiple labs in Europe. The CE Mark was obtained after a successful clinical study that demonstrated the accuracy of Galen Breast in detecting different types of breast cancer. Ibex Medical Analytics aims to offer pathologists a wide range of features to improve the diagnosis of breast cancer. Breast cancer is a common disease affecting women worldwide, and early and accurate diagnosis is crucial for effective treatment. Ibex Medical Analytics uses AI and machine learning to detect early signs of cancer and assist pathologists in diagnosing faster.
CustomersPartners
growth-positive
Ibex obtains CE Mark for AI-powered breast cancer detection
Ibex Medical Analytics has earned a CE Mark for its Galen Breast solution, an AI-powered diagnostic tool for pathologists to detect various types of breast cancer. The solution has been ordered by multiple labs in Europe. The CE Mark was obtained after a successful clinical study that demonstrated the accuracy of Galen Breast in detecting different types of breast cancer. Ibex Medical Analytics aims to offer pathologists a wide range of features to improve the speed and accuracy of breast cancer diagnosis. Breast cancer is the most common disease for women worldwide, and early and accurate diagnosis is crucial for effective treatment decisions. Ibexs AI technology is trained on image samples from biopsy slides to detect early signs of cancer. Ibex Medical Analytics was founded in 2016 and previously deployed its Galen Prostate solution in Frances largest network of pathology labs.
Customers
growth-positive
Philips, Ibex Medical Analytics Partner on AI-Powered Digital Pathology Adoption
Philips has formed a strategic partnership with Ibex Medical Analytics to globally commercialize AI-powered digital pathology solutions. The collaboration aims to address the shortage of trained pathologists and the increasing demands on histopathology due to the growing number of cancer patients. The partnership will enhance reporting efficiency, productivity gains, and diagnostic confidence. This partnership follows recent AI partnership announcements with DiA Imaging Analysis and Lunit, which complement Philips own AI solutions in personal health, precision diagnosis and treatment, and connected care.
PartnersCustomers
growth-positive
Ibex Medical Analytics Raises $38 Million to Accelerate Adoption of AI-powered Cancer Diagnostics in Pathology
Ibex Medical Analytics has raised $38 million in a Series B financing round led by Octopus Ventures and 83North. The companys Galen™ platform uses AI and machine learning technology to improve cancer diagnosis and enable the development of new AI tools for precision medicine. The funding will support the expansion of Ibexs customer base, the growth of its teams, and the development of new AI tools for different tissue types. Ibexs solutions are already in use in labs worldwide and have the potential to transform cancer diagnosis and improve patient outcomes.
Investment
growth-positive
Ibex Medical Analytics Appoints UK Head to Support NHS Adoption of AI-powered Cancer Diagnostics
Ibex Medical Analytics has appointed Richard Nicholson as its Sales Director for the UK and Ireland. Nicholson brings extensive experience in healthcare IT and medical imaging, particularly in the field of digital pathology. He will lead Ibexs commercial team in the UK and Ireland, focusing on accelerating AI adoption in pathology workflows and supporting customer growth. The UK is at the forefront of AI-driven cancer care, and Ibex has the opportunity to implement its clinical-grade solutions in pathology labs across the country. Ibex recently won a share of a £50 million fund as part of the UKs AI in Health and Care Award. Nicholsons appointment is expected to strengthen Ibexs customer base and support the launch of new AI applications.
Management ChangesCustomers
growth-positive
AI Cancer Diagnostics Leader Ibex Medical Analytics Expands to the Americas with Appointment of Joel Duckworth
Ibex Medical Analytics has announced the creation of a United States subsidiary and the appointment of Joel Duckworth as its Chief Revenue Officer for the Americas. Duckworth, an experienced professional in digital pathology, will lead Ibexs commercial activities in the US, Canada, and Latin America. The company aims to further its expansion in the Americas and transition customers to an AI-empowered workflow for pathology. Ibex develops AI-powered cancer diagnostics solutions that help pathologists detect and grade cancer in biopsies. Their solutions, such as Galen Prostate and Galen Breast, are already in routine clinical use and deployed worldwide.
Customers
growth-positive
World's First AI-Solution for Primary Diagnosis of Breast Cancer Deployed by Ibex Medical Analytics and KSM, the Research and Innovation Center of Maccabi Healthcare Services
Ibex Medical Analytics and KSM, the Research and Innovation Center of Maccabi Healthcare Services, announced a pilot of Ibexs Galen Breast solution for AI-powered primary diagnosis of breast cancer at Maccabis Pathology Institute. The pilot includes 2,000 breast biopsies and is the first-ever deployment of an AI application for primary diagnosis of breast cancer. The solution aims to help pathologists diagnose breast biopsies more accurately and efficiently. Ibexs AI solution has been used at Maccabis Pathology Institute since 2018 for second read on breast and prostate biopsies. The integration of AI into primary cancer diagnosis is seen as a significant leap forward in improving diagnostic capabilities.
Partners
growth-positive
Ibex Medical Analytics and Institut Curie Partner to Improve AI-Powered Breast Cancer Detection
Ibex Medical Analytics and Institut Curie have announced a research partnership aimed at improving the diagnosis of breast cancer using AI. Breast cancer is the most common malignant disease in women worldwide, and accurate and timely diagnosis is crucial for treatment decisions and patient survival rates. The partnership will involve the analysis of breast biopsy slides using Ibexs Galen Breast solution, which utilizes AI and machine learning techniques. Multiple pathologists from Institut Curie will independently diagnose the slides, followed by blinded analysis of the AI solutions performance. The collaboration aims to evaluate the utility of AI in diagnosing breast cancer and improve diagnostic accuracy.
Partners
growth-positive
Ibex Medical Analytics Welcomes Dr. David Shulkin, Former Secretary of the VA, and Joe Robinson to its Advisory Board
Ibex Medical Analytics has added David Shulkin, M.D., and Joe Robinson to its advisory board. The new advisors will support Ibexs expansion across the United States and Latin America. Dr. Shulkin previously served as the ninth Secretary of the US Department of Veterans Affairs and has held prominent positions in the healthcare industry. Joe Robinson is a senior healthcare executive with extensive experience in leading multinational companies within the healthcare industry. Ibexs AI-powered cancer diagnostics solutions are in routine clinical use and deployed worldwide. The company sees AI as a key pillar in the digital transformation strategies of large US health networks.
PartnersExpand
growth-positive
Ibex Medical Analytics, the Leader in AI-Powered Cancer Diagnostics, is now ISO 13485 Certified
Ibex Medical Analytics has received ISO 13485 certification, validating its position as a leading and quality-focused solution provider for healthcare organizations. The certification signifies that Ibex meets the most stringent quality standards and regulations for medical devices. Ibex uses AI to develop clinical-grade solutions that help pathologists detect and grade cancer in biopsies. The ISO certification is an important milestone for Ibex as it highlights the high standards and commitment to quality in their solutions. The company aims to address the growing demand for cancer testing and improve diagnostic accuracy in pathology.
CustomersPartners
growth-positive
Ibex Medical Analytics Wins UK Award to Accelerate Adoption of AI-Powered Cancer Detection in the NHS
Ibex Medical Analytics has won a share of a £50 million fund as part of the UKs AI in Health and Care Award for accelerating the rollout of healthcare projects with promising AI technologies across the NHS. Ibexs Galen Prostate solution will be used in 6 NHS hospitals in the largest ever government funded multi-site deployment in the UK. The study will evaluate the AI solutions performance in detecting and grading cancer in prostate biopsies. Ibexs Galen Prostate and Galen Breast solutions are already deployed in pathology labs worldwide. The UK is positioning itself as a world leader in implementing AI technologies in healthcare.
PartnersCustomers
growth-positive
Israel's Ibex Medical Analytics Deploys in Puerto Rico, establishing a foothold in the Americas
Ibex Medical Analytics has deployed its Galen Prostate solution, an AI-based medical solution for prostate cancer, at CorePlus Servicios Clínicos y Patológicos in Carolina, Puerto Rico. This marks the first implementation of AI solutions for cancer detection in pathology in a U.S. laboratory. The deployment includes Whole Slide Imaging (WSI) techniques to digitize glass slides, improving patient care and comfort. The Galen Prostate solution demonstrated an almost 97% accuracy rate in identifying cancer and other clinically significant features in prostate cases. CorePlus will now evaluate all prostate cases using the AI system for quality control. Ibex Medical Analytics specializes in AI solutions for cancer diagnostics and has raised $13.6 million to date. The company was founded in 2016.
CustomersPartners
growth-positive
AI algorithm for detecting prostate cancer shows more than 98% sensitivity, 97% specificity in study
Israeli startup Ibex Medical Analysis has published data on its AI-based pathology system for prostate cancer detection. The study showed high sensitivity and specificity, surpassing previously reported metrics for AI algorithms in pathology. The system also extended into tumor grading, detection of perineural invasion, and tumor sizing. Ibexs CEO highlighted the importance of AI-based pathology systems in addressing the shortage of pathologists. Ibexs competitors in this field include Page.ai and ContextVision. The study was conducted at the University of Pittsburgh Medical Center.
Customers
growth-positive
Ibex Medical Analytics partners with French laboratory network Medipath
Ibex Medical Analytics Ltd. has announced its deployment in Medipath, France’s largest network of pathology labs. This marks the first time an AI-powered solution for cancer detection will be used in pathology in France. Ibexs solution, Galen Prostate, will assist pathologists in Medipath to meet the rising demand in cancer cases. The deployment is seen as a significant step in Ibexs global expansion and extends the cooperation between the two companies. Medipath is Frances largest network of pathology laboratories, collaborating with over 170 hospitals and clinics across the country.
Customers
growth-positive
Israeli AI company partners with medical service to provide better cancer screening for NHS patients
Ibex Medical Analytics has partnered with LDPath Inc. to provide AI applications for cancer detection in the UKs National Health Service. The partnership aims to address the shortage of pathologists in the UK and improve the accuracy and speed of cancer detection. Ibex uses AI to help pathologists detect cancers in biopsies and plans to expand its coverage to different types of cancer. The inclusion of AI technology is expected to reduce waiting times for patients and help identify potential misdiagnoses. Ibex has 25 employees and has completed $13.6 million in Series A funding.
PartnersCustomersInvestment
growth-positive
New AI technology helps pathologists spot cancer
Israeli startup Ibex Medical Analytics has developed an artificial intelligence (AI) application to aid pathologists in diagnosing diseases from tissue biopsies. The Second Read application uses software algorithms to analyse cases in parallel with a pathologist, alerting them to any discrepancies between their diagnosis and the algorithms findings. The application is already in use at Israels Maccabi Healthcare Service for detecting prostate and breast cancer. Ibex, which was launched in 2017, has raised nearly $14 million and has 25 staff in its Tel Aviv offices.
CustomersInvestment
growth-positive
https://www.jpost.com/HEALTH-SCIENCE/Israeli-start-up-Ibex-helps-detect-cancer-using-AI-619083
Tel Aviv-based company Ibex Medical Analytics has received the CE-IVD Mark for its Galen Prostate solution, an AI-based technology that helps identify suspected cancer on prostate core-needle biopsies. The certification marks the first time one of Ibexs products has received conformity to EU health, safety, and protection standards. The Galen Prostate solution addresses the shortage of pathologists and the occurrence of human errors in cancer diagnosis. The algorithm-based technology provides pathologists with a safety net to avoid misdiagnosis, with studies showing a detection rate of over 99% for cancer cases. Ibex is also developing an algorithm for detecting breast cancer and aims to address the shortage of specialists in pathology.
Customers
growth-positive
Ibex Medical Gets CE-IVD Mark for AI Prostate Cancer Detection System
Israeli diagnostics firm Ibex Medical Analytics has received CE-IVD marking for its AI-based prostate cancer detection system, Galen Prostate. The system achieved high accuracy in a clinical study, with an area under the curve of .997, sensitivity of 98.6%, and specificity of 95.6%. Ibex CEO Joseph Mossel stated that the CE-IVD mark will facilitate wider adoption of Galen Prostate in the market.
CustomersPartners
growth-positive
Ibex launches AI-powered diagnostic system for detecting breast cancer in pathology
Ibex Medical Analytics has announced the deployment of its Ibex Second Read System for breast cancer diagnostics at Maccabi Healthcare Services. The system uses AI-powered algorithms to analyze breast biopsies and compare the findings with pathologists diagnoses, alerting in case of discrepancies. The deployment at Maccabis pathology institute enhances the quality control process, reduces diagnostic error rates, and improves workflow efficiency. Ibex previously raised $11 million in Series A funding led by aMoon Fund. The companys partnership with Maccabi Healthcare Services has resulted in the successful deployment of its Second Read system for prostate core needle biopsies diagnosis. The future looks promising for Ibex as pathology labs show interest in their products.
PartnersCustomers
growth-positive
Ibex Medical Analytics and the Kahn-Sagol-Maccabi (KSM) Research and Innovation Institute at Maccabi Healthcare Services Roll Out the First-ever AI-powered Diagnostic System for Detecting Breast Cancer in Pathology
Ibex Medical Analytics, an AI-powered cancer diagnostics company, has partnered with the KSM Research and Innovation Institute at Maccabi Healthcare Services to deploy the Ibex Second Read System for breast at Maccabis pathology institute. The system uses AI to detect and grade cancer in breast biopsies, and is now used in routine clinical practice. The algorithm used by the system was developed by Ibex using advanced machine learning techniques and trained on data sets from Maccabis pathology institute. Ibex has raised $14 million from prominent VC funds and corporate investors.
PartnersCustomersInvestment
growth-positive
Dr. Ajit Singh Joins Ibex Medical Analytics' Advisory Board
Dr. Ajit Singh, managing director of Artiman Ventures, is joining Ibex Medical Analytics advisory board. Ibex provides AI-based cancer diagnosis solutions in pathology labs. Dr. Singhs experience in early stage life sciences companies and artificial intelligence will benefit Ibex as it grows its customer base and expands its product offering. Ibex has recently raised $11 million from VC funds and corporate investors.
Partners
growth-positive
https://www.jpost.com/Opinion/Hillels-Tech-Corner-Ibex-AI-powered-cancer-detection-597434?fbclid=IwAR3_5XrZ280IrJ2IJsXDQuoflVe4oINMlRdG8vISJMvKEgSLkn8NKTA8FOs
Ibex Medical Analytics, a Tel Aviv-based company, is using artificial intelligence (AI) to improve cancer diagnosis. The companys AI system, The Ibex Second Read™ (SR), analyses digital slides and summaries of pathology reports, conducting its own automated diagnosis and comparing it with the results in the pathology report. If a discrepancy is detected, the system raises an alert on the relevant slide, which is then sent back for a second review by the pathologist. The company has attracted $11 million of investments in Series A funding, bringing total investment in the company to $14 million.
PartnersInvestmentExpand
growth-positive
First AI pathology diagnostic system up and running in clinical setting
Ibex Medical Analytics AI-based pathology diagnostic system, called Second Read (SR) System, has been deployed in a live clinical setting at the Institute of Pathology at Maccabi Healthcare Services in Israel. The system assists in the confirmation of prostate cancer by identifying various cell types and features within whole slide images of prostate core needle biopsies. It has demonstrated higher efficiency and accuracy compared to human pathologists, and its use has led to faster diagnoses and better management of population health. Ibex plans to expand the system to address other cancer types and clinical use cases.
CustomersPartners
growth-positive
Ibex Medical Analytics raises $11m
Israeli computational pathology company Ibex Medical Analytics has completed an $11 million Series A financing round led by aMoon Fund. The funds will be used to broaden the companys solutions and global presence, including expansion of the type of tissues and applications supported. Ibexs lead product, a second read system for prostate core needle biopsies diagnosis, has been clinically deployed and will soon be commercially deployed internationally. Ibex plans to expand its engineering team to extend its product offering to additional types of cancer. The company has strategic collaborations with Maccabi Healthcare Services, UPMC, and MediPath. The investors believe Ibex is an early leader in the field of digital and computational pathology.
InvestmentExpand
growth-positive
Dell Backs Cancer Diagnosis Startup Ibex
Tel Aviv-based cancer diagnosis startup Ibex Medical Analytics has raised $11 million in a funding round led by aMoon. The company develops an AI-driven diagnostic system using computer vision, machine learning, and electronic medical records to confirm cancer diagnoses of tissue biopsies. Ibexs product for prostate core needle biopsies was deployed in Israel last year through a partnership with Maccabi Healthcare Services. With the funding, Ibex plans to expand its diagnostic offering to include breast cancer and gastrointestinal cancer.
InvestmentPartnersExpand
growth-positive
Ibex Medical Analytics and UPMC Join Forces for Advancing AI-based Prostate Cancer Diagnostics
Ibex Medical Analytics announces a research collaboration with UPMC and Dr. Liron Pantanowitz to validate the performance of their AI-driven system in prostate cancer diagnosis. The collaboration will further demonstrate the validity of Ibexs system and contribute to making pathology labs more accurate and efficient.
Partners
growth-positive
Ibex Medical Analytics Deploys the First Ever AI-based Digital Pathology Cancer Diagnosis System in Live Clinical Setting, With Immediate Impact on Patient Care
Ibex Medical Analytics has deployed the first ever AI-based digital pathology diagnostic system in a live clinical setting. The system, called Second Read (SR), was deployed in the pathology institute of Maccabi Healthcare Services, one of Ibexs strategic partners. The full-scale deployment followed a pilot period, during which the system identified major errors in retrospective prostate core needle biopsies (PCNBs). Shortly after deployment, the system identified a suspicious PCNB that had been misdiagnosed as benign. Ibexs algorithm utilizes AI and machine learning techniques to identify various cell types and features within whole slide images of PCNBs. The company aims to make the system commercially available.
Partners
Ibex Medical Analytics Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 104 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 14 classification IDs that could be used for matching.
Ibex Medical Analytics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515750537 |
| Crunchbase | ibex-medical-analytics |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-09-06T00:00:00.000Z |
| Created | 2018-09-27T00:00:00.000Z |
| Claimed | Yes |